20 Jul 2018 | 4:23 PM
Research Report

Equity Research Report: Master Pick-Ipca Lab

The domestic business has been a key growth driver for IPCA Lab as the company changed focus from the low margin anti-malarial segment to focus on higher margin chronic/lifestyle diseases.
28 Aug 2015 | 06:00 PM

Aligned with its overall uptrend, it spent nearly 5 months in consolidation within the broader range of 600-760 since Feb, 2015 and breached the same on higher side of late. In line with recent market correction, it has also seen marginal profit taking in last one week; providing fresh opportunity to accumulate in given range of 765-784 with close below stop loss of 710 for the target of 945.